De Novo Crohn's Disease 3 Years Following Immune Checkpoint Inhibitor Therapy.

IF 0.6 Q4 GASTROENTEROLOGY & HEPATOLOGY

ACG Case Reports Journal Pub Date : 2025-04-03 eCollection Date: 2025-04-01 DOI:10.14309/crj.0000000000000944

Matthew G Bell, Manuel Bonfim Braga Neto, Sunanda V Kane

引用次数: 0

Abstract

Presented is a 76-year-old man with metastatic melanoma that was successfully treated with pembrolizumab, an immune checkpoint inhibitor (ICI). He underwent 20 months of ICI treatment without dose limiting side effects. Nearly 18 months after ICI discontinuation, the patient developed intermittent epigastric pain and diarrhea. Owing to mild symptoms, he was not immediately evaluated. Three years after ICI cessation, he was diagnosed with stricturing, jejunal Crohn's disease. He was treated with vedolizumab and displayed clinical and radiographic response to treatment. This case serves as an example of potential gastrointestinal-related, long-term autoimmune implications of ICI therapy, even in patients without acute side effects.

查看原文本刊更多论文

免疫检查点抑制剂治疗后3年新生克罗恩病

本文报告了一位76岁的男性转移性黑色素瘤患者，他成功地接受了免疫检查点抑制剂（ICI）派姆单抗的治疗。他接受了20个月的ICI治疗，没有剂量限制的副作用。ICI停药近18个月后，患者出现间歇性上腹痛和腹泻。由于症状轻微，他没有立即得到评估。停用ICI三年后，他被诊断出患有狭窄的空肠克罗恩病。他接受了维多单抗治疗，并对治疗表现出临床和放射学反应。本病例是ICI治疗的潜在胃肠道相关、长期自身免疫影响的一个例子，即使在没有急性副作用的患者中也是如此。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

ACG Case Reports Journal GASTROENTEROLOGY & HEPATOLOGY-

自引率

14.30%

发文量

170

审稿时长

12 weeks

期刊介绍： ACG Case Reports Journal is a peer-reviewed, open-access publication that provides GI and hepatology fellows, private practice clinicians, and other healthcare providers an opportunity to share interesting case reports with their peers and with leaders in the field. ACG Case Reports Journal publishes case reports, images, videos and letters to the editor in all topics of gastroenterology and hepatology, including: Biliary Colon Endoscopy Esophagus Functional Bowel Disorders Inflammatory Bowel Disease Liver Nutrition and Obesity Pancreas Pathology Pediatric Small Bowel Stomach.